Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis

Ovarian Cancer remains the most common gynecologic malignancy, because of its chemotherapy resistance and relapse. Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, has shown encouraging antitumor activity in several preclinical and clinical trials, while its effect on ovarian Cancer has not been reported. In this study, we investigated the antitumor activity and underlying mechanism of anlotinib in ovarian Cancer. Cell viability was analyzed by Cell Counting Kit-8 assay. Migration was measured by wound-healing assay. The cell cycle distribution and cell Apoptosis rate were detected by flow cytometry. In vivo antitumor effect was analyzed in mouse ovarian carcinoma peritoneal metastasis model. We found that anlotinib inhibited the proliferation of ovarian Cancer cells in a dose- and time- dependent manner by inducing G2/M phase arrest and Apoptosis. Moreover, anlotinib upregulated the the phosphorylation of Histone H3, and expression of p21 protein in vitro. In addition, anlotinib inhibited the migration of ovarian Cancer cells in vitro. Furthermore, anlotinib inhibited tumor growth by inhibiting cell proliferation and suppressing ovarian Cancer angiogenesis in vivo. This study demonstrated the extraordinary anti-ovarian Cancer effect of anlotinib, which may provide a promising therapeutic strategy for ovarian Cancer.

angiogenesis; anlotinib; apoptosis; cell proliferation; ovarian cancer.